Fundraising FoxMetagenomi
Berkeley, US · Founded 2018 · 20 known investors
Find your way into Metagenomi
Each arrow is one introduction. Sign up to fill in the first one.
Ask Dr. Nicole Paulk to introduce you to Brian Thomas
You →Dr. · together at Metagenomi →Brian
Sign up to find every way you can get introduced to Metagenomi
- Your email: who you already know at Metagenomi, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Metagenomi team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Metagenomi Therapeutics is an in vivo genome editing company that uses genetic material sourced from natural environments (metagenomics) to develop a toolbox of editing tools for deletion, integration, and correction of genetic mutations. It focuses on developing genetic medicines to treat diseases with well-understood biology.
Founders & leadership
Metagenomi was founded in 2018 by Brian Thomas.
Board
Investors · 20
How we know: Catalio Capital Management, LP's portfolio page · Not right? Tell us
How we know: RA Capital's portfolio page · funding news · pharmaceutical-technology.com · Not right? Tell us
How we know: Sozo Ventures's portfolio page · funding news · Not right? Tell us
How we know: funding news · the VCSheet dataset · Not right? Tell us
How we know: pharmaceutical-technology.com · Not right? Tell us
How we know: board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · pharmaceutical-technology.com · Not right? Tell us
How we know: pharmaceutical-technology.com · Not right? Tell us
How we know: pharmaceutical-technology.com · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
Also in the syndicate · 8
Reported raises · per SEC filings
Form D private placements$345.1M disclosed across 5 rounds · 2019–2022
▶$95.8MraisedJan 2023 · 25 investors · BiotechnologyRule 506(b)
- Willard DereDirector
- Brian C. ThomasExecutive Officer, Director
- Santhosh PalaniDirector
- Risa StackDirector
- Juergen EckhardtDirector
- Sebastian BernalesDirector
- Offering amount
- $100M
- Amount sold
- $95.8M
- Minimum investment
- $100K
- First sale
- Dec 2022
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
▶$175.4MraisedFeb 2022 · 29 investors · BiotechnologyRule 506(b)
- Risa StackDirector
- Brian ThomasExecutive Officer, Director
- Willard DereDirector
- Juergen EckhardtDirector
- Sebastian BernalesDirector
- Santosh PalaniDirector
- Offering amount
- $175.4M
- Amount sold
- $175.4M
- Minimum investment
- $1M
- First sale
- Jan 2022
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
▶$10MraisedMar 2021 · 2 investors · BiotechnologyRule 506(b)
- Andrew LevinDirector
- Sebastian BernalesDirector
- Andrew FarquharsonDirector
- Brian ThomasExecutive Officer, Director, Promoter
- Juergen EckhardtDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Mar 2021
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
▶$37.5MraisedNov 2020 · 11 investors · Other TechnologyRule 506(b)
- Brian ThomasExecutive Officer, Director, Promoter
- Sebastian BernalesDirector
- Andrew FarquharsonDirector
- Juergen EckhardtDirector
- Offering amount
- $40.2M
- Amount sold
- $37.5M
- First sale
- Nov 2020
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
▶$26.4MraisedAug 2019 · 16 investors · Other TechnologyRule 506(b)
- Brian ThomasExecutive Officer, Director, Promoter
- Andrew FarquharsonDirector
- Jak KnowlesDirector
- Offering amount
- $27.3M
- Amount sold
- $26.4M
- First sale
- Aug 2019
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Metagenomi went on to found or lead other companies.
Frequently asked questions
- What does Metagenomi do?
- Metagenomi Therapeutics is an in vivo genome editing company that uses genetic material sourced from natural environments (metagenomics) to develop a toolbox of editing tools for deletion, integration, and correction of genetic mutations. It focuses on developing genetic medicines to treat diseases with well-understood biology.
- Who founded Metagenomi?
- Metagenomi was founded by Brian Thomas in 2018.
- Who are Metagenomi's investors?
- Metagenomi's investors include Catalio Capital Management, LP, RA Capital, Sozo Ventures, Agent Capital, Frazier Life Sciences, Humboldt, InCube Ventures, Irving Investors and 4 more.
- How much funding has Metagenomi raised?
- Metagenomi has disclosed $345.1M raised across 5 rounds.
- Where is Metagenomi headquartered?
- Metagenomi is headquartered in Berkeley, US.